Matt O'Brien Analyst Performance

Sr. Research Analyst at Piper Sandler

Matt O'Brien is a stock analyst at Piper Sandler in the medical sector, covering 23 publicly traded companies. Over the past year, Matt O'Brien has issued 30 stock ratings, including buy and hold recommendations. While full access to Matt O'Brien's proprietary MarketBeat Analyst Rating is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Matt O'Brien's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rating: Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeat
Average Return: 00.00% 12-Month ROI
Success Rate: 00.00% Profitable Ratings
Total Ratings: 35 Last 4 Years
Buy Recommendations: 78.79% 26 Buy Ratings
Companies Covered: 23 Unique Companies

Ratings Distribution

Rating	Percentage	Count
Strong Buy	0.0%	0 ratings
Buy	78.8%	26 ratings
Hold	21.2%	7 ratings
Sell	0.0%	0 ratings

Out of 33 total stock ratings issued by Matt O'Brien at Piper Sandler, the majority (78.8%) have been Buy recommendations, followed by 21.2% Hold.

Best & Worst Calls

Best Call
00.0%
GMED
Jan 2022
Subscribe to MarketBeat All Access to get analyst recommendation ROI.
Worst Call
000.0%
SRGA
Nov 2021
Subscribe to MarketBeat All Access to get analyst recommendation ROI.

Exchange Coverage

Exchange	Percentage	Count
NASDAQ	69.6% of companies on NASDAQ	16 companies
NYSE	30.4% of companies on NYSE	7 companies

Matt O'Brien, an analyst at Piper Sandler, currently covers 23 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector Icon	Sector	Percentage
	Medical 23 companies	100.0%

Matt O'Brien of Piper Sandler specializes in stock coverage within the Medical sector.

Coverage Industries

Industry	Percentage
MED INSTRUMENTS 13 companies	56.5%
MED PRODUCTS 4 companies	17.4%
MED/DENTAL - SUPP 2 companies	8.7%
MED - BIOMED/GENE 2 companies	8.7%
SURGICAL, MEDICAL, AND DENTAL INSTRUMENTS AND SUPPLIES 1 company	4.3%
SURGICAL APPLIANCES & SUPPLIES 1 company	4.3%

About Matt O'Brien

Matt O'Brien is a senior research analyst and managing director at Piper Sandler covering medical technology and devices. Before joining Piper Sandler in 2014, O'Brien covered medical technology at William Blair for 10 years. Additional work experience includes five years of middle-market investment banking financial advisory work and two years at a healthcare manufacturing and distribution company. O'Brien holds an MBA from the University of Chicago Booth School of Management and a Bachelor of Science from DePaul University in finance.

Follow on LinkedIn

Timeframe

Start Date

End Date

Rating

12-Month ROIAll ROI

Export to Excel

Company	Report Date	Action	Report Date Price	12-Month Price Target	Rating
SI Shoulder Innovations	8/25/2025	Initiated Coverage	$12.63	$18.00	Overweight
TNDM Tandem Diabetes Care	8/7/2025	Downgrade	$14.39	$14.00	Neutral
PRCT PROCEPT BioRobotics	8/7/2025	Lower Price Target	$39.01	$55.00	Overweight
DXCM DexCom	7/31/2025	Boost Price Target	$84.46	$100.00	Overweight
CNMD CONMED	7/31/2025	Lower Price Target	$51.07	$68.00	Overweight
TMDX TransMedics Group	6/4/2025	Reiterated Rating	$130.38	$145.00	Overweight
TMDX TransMedics Group	5/9/2025	Reiterated Rating	$114.25	$125.00	Overweight
GMED Globus Medical	5/9/2025	Lower Price Target	$55.18	$80.00	Overweight
CVRX CVRx	5/9/2025	Lower Price Target	$5.08	$12.00	Overweight
KIDS OrthoPediatrics	5/8/2025	Lower Price Target	$22.99	$30.00	Overweight
Get the Latest News and Ratings for Your Stocks Enter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter.
ATEC Alphatec	5/2/2025	Reiterated Rating	$11.58	$15.00	Overweight
DXCM DexCom	5/2/2025	Lower Price Target	$81.70	$90.00	Overweight
TNDM Tandem Diabetes Care	5/1/2025	Lower Price Target	$19.61	$30.00	Overweight
TMDX TransMedics Group	4/29/2025	Reiterated Rating	$90.00	$105.00	Overweight
GKOS Glaukos	4/15/2025	Lower Price Target	$93.22	$165.00	Overweight
KMTS Kestra Medical Technologies	3/31/2025	Initiated Coverage	$23.43	$27.00	Overweight
TELA TELA Bio	3/21/2025	Downgrade	$2.34	$2.00	Neutral
SGHT Sight Sciences	3/6/2025	Lower Price Target	$2.21	$3.50	Neutral
TFX Teleflex	2/28/2025	Reiterated Rating	$138.99	$140.00	Neutral
ATEC Alphatec	2/27/2025	Boost Price Target	$11.06	$13.00	Overweight
BBNX Beta Bionics	2/24/2025	Initiated Coverage	$20.57	$26.00	Overweight
PODD Insulet	2/21/2025	Boost Price Target	$288.29	$310.00	Overweight
PEN Penumbra	2/19/2025	Reiterated Rating	$270.99	$330.00	Overweight
ATRC AtriCure	2/13/2025	Boost Price Target	$39.55	$50.00	Overweight
STAA STAAR Surgical	2/12/2025	Lower Price Target	$14.94	$16.00	Neutral
CVRX CVRx	2/5/2025	Boost Price Target	$14.89	$20.00	Overweight
BSX Boston Scientific	2/3/2025	Boost Price Target	$103.00	$115.00	Overweight
GKOS Glaukos	1/27/2025	Reiterated Rating	$160.49	$180.00	Overweight
HUMA Humacyte	10/18/2024	Set Price Target	$5.09	$6.00	Neutral
GKOS Glaukos	10/17/2024	Set Price Target	$132.97	$140.00

Stock Forecasts and Research Tools

Today's Ratings

Top-Rated Stocks

More Ratings Tools

Price Forecasts for Popular Stocks

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.